Drug Safety Settlement
Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy. Full Article
- Soldier hacked to death in London in suspected Islamist attack
- FBI says man shot dead while being questioned about Boston bombings
- Short story writer Lydia Davis wins Man Booker International fiction prize
- Gold slips after Bernanke hints at slowing bond buys
- Gold slides as Fed chief hints at reduced bond buying
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Gilead signs deals with Indian cos for low-cost HIV drug
REUTERS - Gilead Sciences Inc (GILD.O) signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug emtricitabine in developing countries.
Under deals with Ranbaxy Laboratories (RANB.NS), Strides Arcolab (STAR.NS) and Mylan Inc's (MYL.O) India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.
Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.
(Reporting by Shailesh Kuber; Editing by Viraj Nair)
- Tweet this
- Share this
- Digg this